antibody

Anti-CD22 [hL22 (Epratuzumab)]

MBS488272

0.2 mg

425 USD

monoclonal

rabbit

nonconjugated

[hL22 (Epratuzumab)]

neutralization, immunoprecipitation, flow cytometry

Antibody

Anti-CD22 [hL22 (Epratuzumab)]

[CD22]

[B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14]

[CD22, partial; B-cell receptor CD22; B-cell receptor CD22; CD22 molecule; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; CD_antigen: CD22]

[CD22]

[CD22; CD22; SIGLEC2; SIGLEC-2; SIGLEC2; BL-CAM; Siglec-2]

Monoclonal

IgG, kappa

[hL22 (Epratuzumab)]

Rabbit

Human, Rhesus Monkey, Cynomolgus Monkey

40

This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cellsurface glycoprotein present on mature B-cells and on many types of malignant B-cells.

Protein A affinity purified

PBS with 0.02% Proclin 300.

Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Blocking; IP; FC

Flow Cytometry (FC/FACS)

Flow Cytometry (FC/FACS)

Flow Cytometry (FC/FACS)

Immunogen: This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of themolecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).

Oncology; Autoimmunity; Biosimilar

Recombinant monoclonal antibody to CD22. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the hybridoma hL22 (Epratuzumab).

Pawlak-Byczkowska et al., Leung et al. Cancer research, 15 August 1989, Vol.49(16), pp.4568-77 &Molecular Immunology, 1995, Vol.32(17), pp.1413-1427

4126455

BAA36576.1

Adaptive Immune System Pathway (1269171); Antigen Activates B Cell Receptor (BCR) Leading To Generation Of Second Messengers Pathway (1269184); B Cell Receptor Signaling Pathway (198909); B Cell Receptor Signaling Pathway (83081); B Cell Receptor Signaling Pathway (492); BCR Signaling Pathway (138058); CD22 Mediated BCR Regulation Pathway (1339141); Cell Adhesion Molecules (CAMs) Pathway (83069); Cell Adhesion Molecules (CAMs) Pathway (480); Hematopoietic Cell Lineage Pathway (83078)

Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

0.2 mg

425 USD